Top

Journal of Diabetes & Metabolic Disorders

Published in:

Open Access 01-06-2020 | Diabetic Nephropathy | Research article

Association of serum sestrin 2 and betatrophin with serum neutrophil gelatinase associated lipocalin levels in type 2 diabetic patients with diabetic nephropathy

Published in: Journal of Diabetes & Metabolic Disorders | Issue 1/2020

Abstract

Purpose

Understanding the pathogenesis and the molecular mechanisms of diabetic nephropathy (DN) helps its timely detection and prevention. The current work aims tomeasure serum sestrin 2 and betatrophin levels in healthy and type diabetic (T2DM)subjects with/or without diabetic nephropathy (DN) and also to test their correlation with serum neutrophil gelatinase associated lipocalin (sNGAL); indicator of DN.

Methods

This study included 96 subjects; 20 healthy (G1) and 76 T2DM [22 normoalbuminuric (G2), 35 microalbuminuric (G3) and 19 macroalbuminuric (G4)]. Serum sestrin 2, betatrophin and NGAL were measured by their corresponding kits.

Results

Significant low levels of serum sestrin 2 andhigh levels of serum betatrophin were found in T2DM group when compared to G1 (p = 0.002,p > 0.001, respectively) and this difference is manifested in G4 followed, in order, by G3, G2 then G1 (p= > 0.001 for both). Also, serum sestrin2 levels showed significant negative correlations with sNGAL in G1 (r = −0.497, p = 0.026), G2 (r = −0.784, p > 0.001), G3 (r = −0.894, p > 0.001) and G4 (r = −0.896, pp. > 0.001) while serum betatrophin levels showed significant positive correlations with sNGAL in G2 (r = 0.681, p > 0.001), G3 (r = 0.518, p > 0.001) and G4 (r = 0.727, p > 0.001).

Conclusion

Serum sestrin 2 levels decrease significantly while betatrophin levels increase significantly in T2DM patients with DN especially those with macroalbuminuria. These levels have significant effect strengths on the indicator of diabetic nephropathy; sNGAL which might indicate theirvaluablerole in the timely detection and prevention of the development of DN.

Mohan H. Textbook of pathology. 5th ed. New Delhi: Jaypee Brothers Medical Publishers; 2005. p. 842–3.

World Health Organization (WHO). Global report on diabetes. WHO Library Cataloguing-in-Publication Data. 2016; ISBN 978 92 4 156525 7. Available at http://who.int.

American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2009;32(1):62–7.

Ma Z, Chen R, Ren H, Guo X, Chen J, Chen L. Endothelial nitric oxide synthase (eNOS) 4b/a polymorphism and the risk of diabetic nephropathy in type 2 diabetes mellitus: a meta-analysis. Meta Gene. 2014;2:50–62.PubMed

Gariani K, de Seigneux S, Pechère-Bertschi A, Philippe J, Martin PY. Diabetic nephropathy: an update. Rev Med Suisse. 2012;8(330):473–9.PubMed

Obineche EN, Adem A. Update in diabetic nephropathy. Int J Diabetes Metab. 2005;13:1–9.

Bangstad HJ, Seljeflot I, Berg TJ, Hanssen KF. Renal tubulointerstitial expansion is associated with endothelial dysfunction and inflammation in type 1 diabetes. Scand J Clin Lab Invest. 2009;69:138–44.PubMed

Caramori M, Fioretto P, Mauer M. Enhancing the predictive value of urinary albumin for diabetic nephropathy. J Am Soc Nephrol. 2006;17:339–52.PubMed

Ellulu MS, Patimah I, Khaza’ai H, Rahmat A, Abed Y. Obesity and inflammation: the linking mechanism and the complications. Arch Med Sci. 2017;13(4):851–63.PubMed

10.

Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011;11(2):98–107.PubMed

11.

Wolowczuk I. Obesity–an inflammatory state. Acta Vet Scand. 2015;57(1):K5. https://doi.org/10.1186/1751-0147-57-S1-K5.PubMedCentral

12.

Lee JH, Budanov AV, Karin M. Sestrins orchestrate cellular metabolism to attenuate aging. Cell Metab. 2013;18(6):792–801.PubMed

13.

Shin BY, Jin SH, Cho IJ, Ki SH. Nrf2-ARE pathway regulates induction of Sestrin-2 expression. Free Radic Biol Med. 2012;53(4):834–41.PubMed

14.

Lee JH, Budanov AV, Talukdar S, Park EJ, Park HL, Park HW, et al. Maintenance of metabolic homeostasis by Sestrin2 and Sestrin3. Cell Metab. 2012;16(3):311–21.PubMedPubMedCentral

15.

Chai D, Wang G, Zhou Z, Yang H, Yu Z. Insulin increases sestrin 2 content by reducing Its degradation through the PI3K/mTOR signaling pathway. Int J Endocrinol. 2015, Article ID 505849, 9 pages.

16.

Chung HS, Hwang HJ, Hwang SY, Kim NH, Seo JA, Kim SG, et al. Association of serum Sestrin2 level with metabolic risk factors in newly diagnosed drug-naïve type 2 diabetes. Diabetes Res Clin Pract. 2018;144:34–41.PubMed

17.

Nourbakhsh M, Sharifi R, Ghorbanhosseini SS, Javad A, Ahmadpour F, Razzaghy Azar M, et al. Evaluation of plasma TRB3 and Sestrin 2 levels in obese and normal-weight children. Child Obes. 2017;13(5):409–14.PubMed

18.

Bolignano D, Donato V, Coppolino G, Campo S, Buemi A, Lacquaniti A, et al. Neutrophil gelatinase–associated lipocalin (NGAL) as a marker of kidney damage. Am J Kidney Dis. 2008;52(3):595–605.PubMed

19.

Devireddy LR, Gazin C, Zhu X, Green MR. A cell surface receptor for lipocalin 24p3 selectively mediates apoptosis and iron uptake. Cell. 2005;123:1293–305.PubMed

20.

Bolignano D, Lacquantiti A, Coppolino G, Donato V, Fazio MR, Nicocia G, et al. Neutrophil gelatinase-associated Lipocalin as an early biomarker of nephropathy in diabetic patients. Kidney Blood Press Res. 2009;32:91–8.PubMed

21.

Lacquaniti A, Donato V, Pintaudi B, Di Vieste G, Chirico V, Buemi A, et al. “Normoalbuminuric” diabetic nephropathy: tubular damage and NGAL. Acta Diabetol. 2013;50(6):935–42.PubMed

22.

Yi P, Park JS, Melton DA. Betatrophin: a hormone that controls pancreatic beta cell proliferation. Cell. 2013;153:747–58.PubMedPubMedCentral

23.

Wang Y, Quagliarini F, Gusarova V, Gromada J, Valenzuela DM, Cohen JC, et al. Mice lacking ANGPTL8 (betatrophin) manifest disrupted triglyceride metabolism without impaired glucose homeostasis. Proc Natl Acad Sci U S A. 2013;110:16109–14.PubMedPubMedCentral

24.

Fu Z, Berhane F, Fite A, Seyoum B, Abou-Samra AB, Zhang R. Elevated circulating lipasin/betatrophin in human type 2 diabetes and obesity. Sci Rep. 2014;4:5013.PubMedPubMedCentral

25.

Gomez-Ambrosi J, Pascual E, Catalan V, Rodriguez A, Ramirez B, Silva C, et al. Circulating betatrophin concentrations are decreased in human obesity and type 2 diabetes. J Clin Endocrinol Metab. 2014;99:E2004–9.PubMed

26.

Al-Rawashdeh A, Kasabri V, Bulatova N, Akour A, Zayed A, Momani M, et al. The correlation between plasma levels of oxytocin and betatrophin in non-diabetic and diabetic metabolic syndrome patients: A cross sectional study from Jordan. Diabetes Metab Syndr: Clinical Research and Reviews. 2017;11(1):59–67.

27.

Espes D, Martinell M, Carlsson PO. Increased circulating betatrophin concentrations in patients with type 2 diabetes. Int J Endocrinol. 2014;2014. https://doi.org/10.1155/2014/323407.

28.

Chen CC, Susanto H, Chuang WH, Liu TY, Wang CH. Higher serum betatrophin level in type2 diabetes subjects is associated with urinary albumin excretion and renal function. Cardiovasc Diabetol. 2016;15:3.PubMedPubMedCentral

29.

Rodby RA, Rohde RD, Sharon Z, Pohl MA, Bain RP, Lewis EJ. The urine protein to creatinine ratio as a predictor of 24-hour urine protein excretion in type 1 diabetic patients with nephropathy. The collaborative study group. Am J Kidney Dis. 1995;26:904–9.PubMed

30.

Parchwani DN, Upadhyah AA. Diabetic nephropathy: progression and pathophysiology. Int J Med Sci Public Health. 2012;1(2):59–70.

31.

Budanov AV. Stress-responsive sestrins link p53 with redox regulation and mammalian target of rapamycin signaling. Antioxid Redox Signal. 2011;15(6):1679–90.PubMedPubMedCentral

32.

Budanov AV, Sablina AA, Feinstein E, Koonin EV, Chumakov PM. Regeneration of peroxiredoxins by p53-regulated sestrins, homologs of bacterial AhpD. Science. 2004;304(5670):596–600.PubMed

33.

Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006;124(3):471–84.PubMed

34.

Howell JJ, Ricoult SJ, Ben-Sahra I, Manning BD. A growing role for mTOR in promoting anabolic metabolism. Biochem Soc Trans. 2013;41(4):906–12.PubMed

35.

Eid AA, Lee DY, Roman LJ, Khazim K, Gorin Y. Sestrin 2 and AMPK connect hyperglycemia to Nox4-dependent endothelial nitric oxide synthase uncoupling and matrix protein expression. Mol Cell Biol. 2013;33(17):3439–60.PubMedPubMedCentral

36.

Ro SH, Xue X, Ramakrishnan SK, Ck C, Namkoong S, Jang I, et al. Tumor suppressive role of sestrin2 during colitis and colon carcinogenesis. eLife. 2016;5:e12204.PubMedPubMedCentral

37.

Maurer L, Schwarz F, Fischer-Rosinsky A, Schlueter A, Brachs S, Mo M, et al. Renal function is independently associated with circulating betatrophin. PLoS One. 2017;12(3).

Title: Association of serum sestrin 2 and betatrophin with serum neutrophil gelatinase associated lipocalin levels in type 2 diabetic patients with diabetic nephropathy
Publication date: 01-06-2020
Keyword: Diabetic Nephropathy
Published in: Journal of Diabetes & Metabolic Disorders / Issue 1/2020
Electronic ISSN: 2251-6581
DOI: https://doi.org/10.1007/s40200-020-00498-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2020

Transcranial direct current stimulation improves quality of life and physical fitness in diabetic polyneuropathy: a pilot double blind randomized controlled trial

Safety and efficacy of Berberis integerrima root extract in patients with type 2 diabetes. A parallel intervention based triple blind clinical trial

Correction to: The role of using different reference population in the prevalence of low BMD in the thalassemia patients

Helicobacter pylori infection and type 1 diabetes mellitus in children

Evaluation of skin absorption of the Citrullus colocynthis in treatment of type II diabetic patients

Deep learning approach for diabetes prediction using PIMA Indian dataset

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials